Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases. Our commitment is to make every effort to support patients in need of treatment options.
(updated Nov 2022)
At this time, patients in the US and EU have the possibility to access tabelecleucel through one of our clinical trials.
In the US, for the next 3-6 months, the expanded access 901 protocol and consideration of single patient use requests of tabelecleucel are temporarily paused.
Periodic updates regarding the resumption of this program will be provided on this website.
In the EU, Atara will consider providing an individual patient with access to investigational product candidates through an expanded access study. A treating physician may request information about how to apply for access to one of Atara’s investigational product candidates by contacting Atara. Atara will use reasonable efforts to respond and acknowledge each request within one (1) business day of submission. All physicians who receive Atara’s investigational product candidate are required to comply with all applicable laws and regulations, and contractual conditions, including those relating to safety reporting.
Atara will use the following criteria to review each request:
Each request will be evaluated individually to assess the above criteria.